Forward to: Finance Team

Biotech Funding Intelligence
Workflows

Ten agent workflows for the Finance Team — IPO pipeline tracking, venture funding monitoring, grant intelligence, capital markets analysis, investor sentiment signals, biotech index analysis, secondary offering intelligence, debt financing tracking, crossover investor monitoring, and funding strategy dashboard — enabling data-driven financial decisions powered by domain intelligence.

These workflows display realistic demo data for demonstration. In production, the agents connect to your real biotech and life sciences data via MCP services or CSV import.
Deployment Options
The entire platform is available as a self-hosted solution or managed service
Self-Hosted
RECOMMENDED FOR ENTERPRISE
Deploy the entire platform on your own infrastructure. Your data never leaves your environment. Bring your own LLM API key (OpenAI, Claude, Gemini) or use local LLMs. Full source code delivered.
Complete source code (Python agents, PHP dashboards, MCP services)
Data stays on your servers — no external data transfer
MCP connectors for your existing data sources, APIs, and internal platforms
Custom integration and onboarding support available
$999
2 AI Agents
5 integration hrs
$1,999
5 AI Agents
10 integration hrs
$3,999
10 AI Agents
20 integration hrs
one-time license + (optional) $999/yr updates
Managed Platform
FOR AGENCIES & TEAMS
We host and operate the platform for you. Upload data or connect your platforms via secure MCP services or using API. No infrastructure management needed.
Fully managed — no DevOps required on your side
Secure data upload or API-based MCP integration
Dashboard access with your own branded login
Automatic updates and new agent releases
$999/mo
2 AI Agents
5 integration hrs
$1,999/mo
5 AI Agents
10 integration hrs
$3,999/mo
10 AI Agents
20 integration hrs
includes hosting, updates & support
* price may be higher in cases of very high AI processing volumes/demands
Both options include MCP services with connectors for your existing data sources, APIs, and internal platforms. Data dictionaries define the schema contract between each agent and your data sources.
See example of production dashboards: Programmatic Trading AI Agent Dashboards →

1IPO Pipeline Tracking

AI agent monitors biotech company domains for IPO preparation signals — S-1 filings, underwriter engagement, audit completions, and board composition changes that indicate imminent public offerings.

1
Track IPO Preparation Signals
/investors/leadership/careersDomain AgesOpenPageRank
BIOTECH IPO PIPELINE — Q1 2026 ════════════════════════════════════════════════════════ S-1 FILED — IPO IMMINENT: example-biotech-ipo.com — mRNA Oncology /investors: S-1 filed — $200M target raise /leadership: Added 3 independent directors (public board prep) /careers: CFO + Controller + IR Director hired SIGNAL: IPO within 30 days — evaluate as investment IPO PREPARATION — 3-6 MONTHS OUT: stealth-gene-therapy.com /leadership: Big 4 audit firm engaged /careers: SOX compliance + IR postings Domain Age: 1,800 days | PageRank: 3.4 SIGNAL: IPO preparation — likely Q3 2026 IPO MARKET SUMMARY: Biotech IPOs (YTD 2026): 18 completed ($3.2B raised) Average first-day pop: +22% Pipeline: 24 S-1 filings pending

2Venture Funding Monitor

AI agent monitors biotech startup domains for venture funding signals — Series A through D rounds, lead investor identification, and capital deployment priorities.

1
Track Venture Funding Activity
/press/about/investorsDomain Ages
BIOTECH VENTURE FUNDING — Q1 2026 ════════════════════════════════════════════════════════ NOTABLE SERIES B+ ROUNDS: chroma-medicine.com — Epigenetic Editing /press: $135M Series B — led by ARCH + Flagship /about: 40 employees | Platform: gene silencing SIGNAL: Top-tier investors — validate epigenetic approach laronde.com — Endless RNA /press: $440M Series B — Flagship portfolio /about: Self-amplifying RNA platform SIGNAL: Massive round — potential platform disruptor VENTURE FUNDING SUMMARY: Total biotech VC (Q1 2026): $8.4B (+28% YoY) Median Series A: $48M | Series B: $120M Hot sectors: AI drug discovery, gene editing, obesity

3Grant Funding Intelligence

AI agent monitors NIH, BARDA, and other grant-funding agency domains to track non-dilutive funding opportunities, awarded grants, and government priorities in biotech and pharma research.

1
Track Grant Opportunities
/products/press/aboutCountries
GRANT FUNDING INTELLIGENCE ════════════════════════════════════════════════════════ nih.gov — NIH Funding /press: FY2026 budget: $48.5B (+3.2%) Priority areas: AI in drug discovery, pandemic preparedness SIGNAL: $2.1B allocated to ARPA-H — novel mechanisms medicalcountermeasures.gov — BARDA /products: 14 new BAAs published — MCM development /press: $800M for next-gen antiviral platforms OPPORTUNITY: $50-200M contracts available for our antiviral GRANT FUNDING AWARDED (OUR SECTOR): NIH R01 grants in our TAs: $340M this quarter BARDA contracts: $1.2B awarded YTD

4Capital Markets Analysis

AI agent monitors biotech capital markets activity by tracking secondary offerings, ATM programs, convertible debt issuances, and capital allocation strategies across the sector.

1
Analyze Capital Markets Activity
/investors/press/legalOpenPageRank
BIOTECH CAPITAL MARKETS — Q1 2026 ════════════════════════════════════════════════════════ SECONDARY OFFERINGS: Total raised (YTD): $12.8B across 45 offerings Average discount to market: 6.2% CONVERTIBLE DEBT: Issuance volume: $4.2B (8 deals) Average coupon: 2.8% | Average premium: 35% CASH RUNWAY RISK: Biotech companies with <12 months cash: 82 companies Likely capital raises next quarter: 28 expected SIGNAL: Capital-constrained biotechs may seek partnerships

5Investor Sentiment Tracking

AI agent monitors investor-focused biotech domains to track analyst ratings, price targets, institutional ownership changes, and conference attendance patterns as indicators of market sentiment.

1
Track Investor Sentiment
/investors/events/pressOpenPageRank
INVESTOR SENTIMENT INTELLIGENCE ════════════════════════════════════════════════════════ SECTOR SENTIMENT: XBI (Biotech ETF): +18% YTD — risk appetite improving IPO window: OPEN — strong demand for quality biotechs ANALYST COVERAGE CHANGES: Our company: 3 new coverage initiations (Buy/Outperform) Average price target: $85 — 32% upside INSTITUTIONAL OWNERSHIP: Baker Brothers: Increased position 15% OrbiMed: New position — $120M stake SIGNAL: Smart money accumulating — positive catalyst expected

6Crossover Investor Intelligence

AI agent monitors crossover investor activity — tracking late-stage private rounds led by public market investors as signals for upcoming IPOs and public company investment thesis.

1
Track Crossover Activity
/investors/press/aboutDomain Ages
CROSSOVER INVESTOR INTELLIGENCE ════════════════════════════════════════════════════════ CROSSOVER ROUNDS (LAST 90 DAYS): 8 biotech crossover rounds completed Total raised: $2.4B Top crossover investors: Fidelity, T Rowe, Wellington IPO PREDICTION FROM CROSSOVERS: Companies with crossover rounds → IPO within 12 months: 78% Average crossover-to-IPO timeline: 6-9 months SIGNAL: 6 of 8 crossover biotechs likely IPO 2026

7Competitor Financial Health

AI agent monitors competitor financial health by tracking cash positions, burn rates, debt maturities, and capital structure changes — identifying potential partnership or acquisition opportunities from distressed companies.

1
Assess Competitor Financial Health
/investors/press/careersOpenPageRank
COMPETITOR FINANCIAL HEALTH ASSESSMENT ════════════════════════════════════════════════════════ STRONG FINANCIAL POSITION: regeneron.com — Cash $12.4B | Net cash positive vertexpharm.com — Cash $10.8B | FCF $4.2B/year FINANCIALLY DISTRESSED: distressed-biotech.com /investors: Cash $45M | Burn rate $28M/quarter /careers: -60% postings — workforce reduction SIGNAL: 5-month runway — fire sale likely OPPORTUNITY: Pipeline asset worth $200-400M at steep discount DISTRESS METRICS: Companies with <6 months cash: 34 Expected wind-downs: 12 this year

8Debt Financing Tracker

AI agent monitors biotech debt financing activity — tracking royalty monetization, term loans, credit facilities, and revenue-based financing that indicate capital allocation strategies.

1
Track Debt Financing Activity
/investors/press/legalOpenPageRank
BIOTECH DEBT FINANCING TRACKER ════════════════════════════════════════════════════════ ROYALTY MONETIZATION: royaltypharma.com /investors: $2.8B deployed in 2025 | 12 new royalty assets /press: Acquired royalty on top-10 selling drug SIGNAL: Royalty financing attractive for non-dilutive capital VENTURE DEBT: herculescapital.com — $1.4B biotech portfolio Average term: 36 months | Rate: SOFR + 5-8% SIGNAL: Venture debt tightening — higher rates REVENUE-BASED FINANCING: Deals completed: 8 this quarter ($1.1B total) Average cost of capital: 12-18% implied

9Biotech Index & ETF Analysis

AI agent monitors biotech index composition, ETF flows, and sector rotation signals to provide macro-level intelligence on biotech investment trends and market positioning.

1
Analyze Biotech Sector Flows
/investors/products/pressIAB Categories
BIOTECH SECTOR ANALYSIS ════════════════════════════════════════════════════════ INDEX PERFORMANCE (YTD 2026): XBI (S&P Biotech ETF): +18% IBB (iShares Nasdaq Biotech): +14% NBI (Nasdaq Biotech Index): +15% ETF FLOWS: XBI: $2.4B inflows (last 3 months) IBB: $1.8B inflows SIGNAL: Sector rotation into biotech — risk appetite returning SECTOR VALUATION: XBI EV/Revenue: 4.8x (vs 5-year avg 5.2x) SIGNAL: Below historical average — value opportunity

10Funding Strategy Dashboard

AI agent synthesizes all funding intelligence into an executive dashboard — providing leadership with visibility into capital markets, competitor financial health, and fundraising environment.

1
Generate Funding Dashboard
/investors/press/aboutOpenPageRankIAB Categories
FUNDING DASHBOARD — FEBRUARY 2026 ════════════════════════════════════════════════════════ MARKET CONDITIONS: IPO window: OPEN | Investor sentiment: Positive XBI performance: +18% YTD FUNDRAISING ENVIRONMENT: VC funding (Q1): $8.4B (+28% YoY) IPOs completed: 18 ($3.2B raised) Secondary offerings: 45 ($12.8B raised) DISTRESSED OPPORTUNITIES: Companies <6 months cash: 34 Potential fire sale assets: $2-4B estimated value
2
Generate Funding Report

Biotech Funding Report — February 2026

EXECUTIVE SUMMARY ──────────────────────────────────────── Companies monitored for funding signals: 1,800 domains IPO filings tracked: 24 pending VC rounds monitored: 140+ this quarter Distressed biotechs: 34 with <6 months cash KEY INSIGHTS Biotech capital markets significantly improved — IPO window open. Crossover investor activity accelerating — 8 rounds completed. Distressed biotechs creating acquisition opportunities at discount. Grant funding priorities shifting toward AI and pandemic preparedness. Royalty monetization emerging as preferred non-dilutive financing.
Get in Touch

Interested in AI Agent Domain Intelligence?

For pricing, subscription options, custom database builds, or enterprise partnerships — contact us below.

Power Your AI Agents with Domain Intelligence

Subscribe to the AI Agent Domain Database — continuous access to 102M domains, 20 page types each, quarterly refreshes, and real-time change signals.

AI Agent Database View Pricing

Annual subscription includes quarterly data refreshes, change detection alerts, and priority API access.